VivoSeq
Other

Digestive System Disease

2

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Digestive System Disease is an early-stage landscape with 2 programs across 2 companies. The most active players are Eli Lilly, Hikma Pharmaceuticals LLC. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 3H

Hikma Pharmaceuticals LLC

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 32

Lidocaine IV

Kasr El Aini Hospital

Morphine

Hikma Pharmaceuticals LLC

Approved
No programs

Analysis

Trial Status

1

clinical trials

Not yet recruiting1 · 100%

Clinical Trials

Trial Activity

Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Intravenous Lidocaine Versus Placebo in Patients Receiving Analgesic Morphine Rachi Anesthesia for Major Digestive or Abdominal Surgery by Laparotomy.
Not yet recruiting·GGCS Ramsay Santé pour l'Enseignement et la Recherche·Phase 3·NCT07076641·76 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)